Safety and Pharmacokinetics of Exebacase in an Infant With Disseminated Staphylococcus aureus Infection.
Clin Infect Dis
; 75(2): 338-341, 2022 08 25.
Article
in En
| MEDLINE
| ID: mdl-34894129
ABSTRACT
Exebacase, an antistaphylococcal lysin produced from a bacteriophage-encoded gene, is a promising adjunctive therapy for severe methicillin-resistant Staphylococcus aureus infections. We describe the first infant to receive exebacase, dosing, and pharmacokinetics. Exebacase may be safe and efficacious in children; however, further clinical trials are needed to optimize dosing.
Key words
Full text:
1
Database:
MEDLINE
Main subject:
Staphylococcal Infections
/
Methicillin-Resistant Staphylococcus aureus
Limits:
Child
/
Humans
/
Infant
Language:
En
Journal:
Clin Infect Dis
Journal subject:
DOENCAS TRANSMISSIVEIS
Year:
2022
Type:
Article
Affiliation country:
United States